1. Academic Validation
  2. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases

Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases

  • J Med Chem. 2020 Jul 23;63(14):7491-7507. doi: 10.1021/acs.jmedchem.9b01976.
Scott J Hecker 1 K Raja Reddy 1 Olga Lomovskaya 1 David C Griffith 1 Debora Rubio-Aparicio 1 Kirk Nelson 1 Ruslan Tsivkovski 1 Dongxu Sun 1 Mojgan Sabet 1 Ziad Tarazi 1 Jonathan Parkinson 1 Maxim Totrov 2 Serge H Boyer 1 Tomasz W Glinka 1 Orville A Pemberton 3 Yu Chen 3 Michael N Dudley 1
Affiliations

Affiliations

  • 1 Qpex Biopharma, Inc., 6275 Nancy Ridge Drive, Suite 100, San Diego, California 92121, United States.
  • 2 Molsoft LLC, 11199 Sorrento Valley Road, San Diego, California 92121, United States.
  • 3 Department of Molecular Medicine, University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, Florida 33612, United States.
Abstract

Despite major advances in the β-lactamase inhibitor field, certain enzymes remain refractory to inhibition by agents recently introduced. Most important among these are the class B (metallo) Enzyme NDM-1 of Enterobacteriaceae and the class D (OXA) enzymes of Acinetobacter baumannii. Continuing the boronic acid program that led to vaborbactam, efforts were directed toward expanding the spectrum to allow treatment of a wider range of organisms. Through key structural modifications of a bicyclic lead, stepwise gains in spectrum of inhibition were achieved, ultimately resulting in QPX7728 (35). This compound displays a remarkably broad spectrum of inhibition, including class B and class D enzymes, and is little affected by porin modifications and efflux. Compound 35 is a promising agent for use in combination with a β-lactam Antibiotic for the treatment of a wide range of multidrug resistant Gram-negative Bacterial infections, by both intravenous and oral administration.

Figures
Products